Headlines
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
Published by Global Banking and Finance Review
Posted on April 18, 2025
Published by Global Banking and Finance Review
Posted on April 18, 2025
(Reuters) -The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
(Reporting by Christy Santhosh and Gnaneshwar Rajan in Bengaluru; Editing by Alison Williams)
Explore more articles in the Headlines category

